Summary
This 2020 Nature Medicine study identifies elevated IL-8 as a potential predictive biomarker inversely associated with clinical benefit from PD-L1 blockade immunotherapy. The findings, as suggested by the title, propose that high IL-8 in both systemic circulation and tumour microenvironment may be indicative of reduced responsiveness to checkpoint inhibitor therapy, potentially enabling stratification of patients likely to benefit from this treatment approach.
UK applicability
The findings are directly applicable to UK oncology and immunotherapy clinical practice, supporting development of patient selection criteria and biomarker-driven treatment algorithms within NHS cancer centres and contributing to precision medicine approaches in checkpoint inhibitor therapy.
Key measures
Systemic IL-8 levels, tumour-associated IL-8 expression, objective response rate, disease progression, immune checkpoint inhibitor efficacy
Outcomes reported
The study investigated the relationship between systemic and tumour-associated interleukin-8 (IL-8) levels and clinical benefit from PD-L1 checkpoint inhibitor blockade in cancer patients. The analysis measured IL-8 concentrations and correlated them with therapeutic response outcomes.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.